Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
643
mi
from 43215
Boston, MA
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis
481
mi
from 43215
New York, NY
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
353
mi
from 43215
Chapel Hill, NC
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
339
mi
from 43215
Nashville, TN
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
339
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
4052
mi
from 43215
Bruxelles,
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
4052
mi
from 43215
Bruxelles,
Click here to add this to my saved trials
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
Feasibility of an Evidence-based Walking Program in a Sample of Cancer Patients >60 Years of Age Undergoing Cytotoxic Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Cancer Hospital
354
mi
from 43215
Chapel Hill, NC
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
Feasibility of an Evidence-based Walking Program in a Sample of Cancer Patients >60 Years of Age Undergoing Cytotoxic Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Cancer Hospital
354
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Alabama Oncology
492
mi
from 43215
Birmingham, AL
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Alabama Oncology
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Comprehensive Blood and Cancer Center
1983
mi
from 43215
Bakersfield, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Comprehensive Blood and Cancer Center
1983
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
1984
mi
from 43215
Santa Monica, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
1984
mi
from 43215
Santa Monica, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
873
mi
from 43215
Sarasota, FL
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
873
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center For Cancer Care
185
mi
from 43215
Goshen, IN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center For Cancer Care
185
mi
from 43215
Goshen, IN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cornell University
480
mi
from 43215
New York, NY
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cornell University
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Vanderbilt
335
mi
from 43215
Nashville, TN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Vanderbilt
335
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
910
mi
from 43215
Dallas, TX
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Utah
1511
mi
from 43215
Salt Lake City, UT
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Utah
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
2013
mi
from 43215
Tacoma, WA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
2013
mi
from 43215
Tacoma, WA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
San Diego Pacific Oncology and Hematology Associates
1947
mi
from 43215
Encinitas, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
San Diego Pacific Oncology and Hematology Associates
1947
mi
from 43215
Encinitas, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Southern California (USC)
1974
mi
from 43215
Los Angeles, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Southern California (USC)
1974
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
2108
mi
from 43215
San Francisco, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Parkview Research Center
135
mi
from 43215
Fort Wayne, IN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Parkview Research Center
135
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Greenville Health System, Institute for Translational Oncology Research
360
mi
from 43215
Greenville, SC
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Greenville Health System, Institute for Translational Oncology Research
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
1649
mi
from 43215
Scottsdale, AZ
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
1649
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
1955
mi
from 43215
Duarte, CA
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Akron General Medical Center
108
mi
from 43215
Akron, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Akron General Medical Center
108
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Akron City/St. Thomas Hospital (Summa Health System)
109
mi
from 43215
Akron, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Akron City/St. Thomas Hospital (Summa Health System)
109
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Summa Barberton (Summa Health System)
103
mi
from 43215
Barberton, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Summa Barberton (Summa Health System)
103
mi
from 43215
Barberton, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy Clermont
85
mi
from 43215
Batavia, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy Clermont
85
mi
from 43215
Batavia, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
103
mi
from 43215
Canton, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
103
mi
from 43215
Canton, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Aultman Hospital
102
mi
from 43215
Canton, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Aultman Hospital
102
mi
from 43215
Canton, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Adena Health System
43
mi
from 43215
ChillIcothe, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Adena Health System
43
mi
from 43215
ChillIcothe, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
The Christ Hospital
98
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
The Christ Hospital
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital (TriHealth)
97
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital (TriHealth)
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Bethesda North Hospital (TriHealth)
87
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Bethesda North Hospital (TriHealth)
87
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy Anderson
99
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy Anderson
99
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy West
99
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy West
99
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Jewish Hospital
89
mi
from 43215
Cincinnati, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Jewish Hospital
89
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Metrohealth
123
mi
from 43215
Cleveland, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Metrohealth
123
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Fairview Hospital
127
mi
from 43215
Cleveland, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Fairview Hospital
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mount Carmel East Hospital
1
mi
from 43215
Columbus, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mount Carmel East Hospital
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
6
mi
from 43215
Columbus, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Grant Medical Center
1
mi
from 43215
Columbus, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Grant Medical Center
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mount Carmel West Hospital
1
mi
from 43215
Columbus, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mount Carmel West Hospital
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials